Fig. 1From: Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal RanibizumabMean Number of Injections and Visual Acuity Gain. The maximum gain in vision from baseline occurred after the first injection and was sustained through week 48. However, the patients required further injections during the follow-up to maintain the gain in visionBack to article page